We observed significantly increased levels of tumor-infiltrating NK cells (CD56+) and enhanced cytotoxic activities of these NK cells (CD56+CD107a+) in the post-BRB specimens compared to the pre-BRB specimens from the CRC patients (Figure 5). The gene discussed is LAMP1; the disease is colorectal carcinoma.